53 documents found, page 1 of 6
Paving the way for a non‐antibiotic and microbiota friendly therapy for Helicob...
Seabra, CL; Pinho, AS; Nunes, C; Amorim, I; Pedro, N; Henriques, P; Monteiro, C; Gomes, J; Machado, C; Gartner, F; Pereira, L; Reis, S; Reis, CABackground: The World Health Organization has identified Helicobacter pylori, a Gram-negative bacterium responsible for several gastric disorders, as one of the pathogenic bacteria that requires newer non-antibiotic approaches for its management. We previously demonstrated that nanostructured lipid carriers (NLC) loaded with docosahexaenoic acid (DHA-NLC)have excellent in vitro performance against H. pylori. Ma...
Extracellular vesicles in tumor-adipose tissue crosstalk: key drivers and thera...
Ramos, CC; Pires, J; Gonzalez, E; Garcia-Vallicrosa, C; Reis, CA; Falcon-Perez, JM; Freitas, DCancer cachexia is a complex metabolic syndrome characterized by unintentional loss of skeletal muscle and body fat. This syndrome is frequently associated with different types of cancer and negatively affects the prognosis and outcome of these patients. It involves a dynamic interplay between tumor cells and adipose tissue, where tumor-derived extracellular vesicles (EVs) play a crucial role in mediating inter...
Differential Protein and Glycan Packaging into Extracellular Vesicles in Respon...
Martins, ÁM; Lopes, TM; Diniz, F; Pires, J; Osorio, H; Pinto, F; Freitas, D; Reis, CAAlterations of the glycosylation machinery are common events in cancer, leading to the synthesis of aberrant glycan structures by tumor cells. Extracellular vesicles (EVs) play a modulatory role in cancer communication and progression, and interestingly, several tumor-associated glycans have already been identified in cancer EVs. Nevertheless, the impact of 3D tumor architecture in the selective packaging of ce...
Glycosylation of cancer extracellular vesicles: Capture strategies, functional ...
Martins, ÁM; Ramos, CC; Freitas, D; Reis, CAGlycans are major constituents of extracellular vesicles (EVs). Alterations in the glycosylation pathway are a common feature of cancer cells, which gives rise to de novo or increased synthesis of particular glycans. Therefore, glycans and glycoproteins have been widely used in the clinic as both stratification and prognosis cancer biomarkers. Interestingly, several of the known tumor-associated glycans have al...
P-selectin glycoprotein ligand 1 promotes T cell lymphoma development and disse...
Pereira, JL; Cavaco, P; Silva, RC; Pacheco-Leyva, I; Mereiter, S; Pinto, R; Reis, CA; Santos, NRP-selectin glycoprotein ligand-1 (PSGL-1) is a membrane-bound glycoprotein expressed in lymphoid and myeloid cells. It is a ligand of P-, E- and L-selectin and is involved in T cell trafficking and homing to lymphoid tissues, among other functions. PSGL-1 expression has been implicated in different lymphoid malignancies, so here we aimed to evaluate the involvement of PSGL-1 in T cell lymphomagenesis and dissem...
Mycobacterium tuberculosis infection up-regulates sialyl lewis x expression in ...
Matos, R; Fonseca, KL; Mereiter, S; Maceiras, AR; Gomes, J; Vilaplana, C; Gärtner, F; Rodrigues, P; Reis, CA; Saraiva, M; Magalhães, AGlycans display increasingly recognized roles in pathological contexts, however, their impact in the host-pathogen interplay in many infectious diseases remains largely unknown. This is the case for tuberculosis (TB), one of the ten most fatal diseases worldwide, caused by infection of the bacteria Mycobacterium tuberculosis. We have recently reported that perturbing the core-2 O-glycans biosynthetic pathway in...
Chitosan-olive oil microparticles for phenylethyl isothiocyanate delivery: Opti...
Coscueta, ER; Sousa, AS; Reis, CA; Pintado, MPhenylethyl isothiocyanate (PEITC), a chemopreventive compound, is highly reactive due to its considerably electrophilic nature. Furthermore, it is hydrophobic and has low stability, bioavailability and bioaccessibility. This restricts its use in biomedical and nutraceutical or food applications. Thus, the encapsulation of this agent has the function of overcoming these limitations, promoting its solubility in ...
Heparan sulfate glycosaminoglycans: (un)expected allies in cancer clinical mana...
Faria-Ramos, I; Poças, J; Marques, C; Santos-Antunes, J; Macedo, G; Reis, CA; Magalhães, AIn an era when cancer glycobiology research is exponentially growing, we are witnessing a progressive translation of the major scientific findings to the clinical practice with the overarching aim of improving cancer patients’ management. Many mechanistic cell biology studies have demonstrated that heparan sulfate (HS) glycosaminoglycans are key molecules responsible for several molecular and biochemical proces...
The extracellular small leucine-rich proteoglycan biglycan is a key player in g...
Pinto, F; Santos-Ferreira, L; Pinto, MT; Gomes, C; Reis, CABiglycan (BGN gene), an extracellular proteoglycan, has been described to be associated with cancer aggressiveness. The purpose of this study was to clarify the clinical value of biglycan as a biomarker in multiple independent GC cohorts and determine the in vitro and in vivo role of biglycan in GC malignant features. We found that BGN is commonly over-expressed in all analyzed cohorts, being associated with di...
Heparan Sulfate Biosynthesis and Sulfation Profiles as Modulators of Cancer Sig...
Marques, C; Reis, CA; Vivès, RR; Magalhães, AHeparan Sulfate Proteoglycans (HSPGs) are important cell surface and Extracellular Matrix (ECM) maestros involved in the orchestration of multiple cellular events in physiology and pathology. These glycoconjugates bind to various bioactive proteins via their Heparan Sulfate (HS) chains, but also through the protein backbone, and function as scaffolds for protein-protein interactions, modulating extracellular li...